I

Integer Holdings Corporation

Medical device CDMO for cardiac devices

Senior Quality Manager

Full-TimeUpdated on 10/15/2026
No salary listed
Senior, Expert
Bachelor's, Master's
Montevideo, Montevideo Department, Uruguay
In Person
Manufacturing Quality & TestValidation, Compliance & Quality Systems

About the job

Requirements
  • A bachelor's degree in engineering or a related technical field is required; a master's degree is preferred.
  • At least 8 years of experience in a manufacturing environment where ISO standards governance and/or regulatory compliance were expected.
  • Prior supervisory or leadership experience.
  • Technical competence using and deploying root cause analysis, problem-solving methods, statistical analysis, and capability assessments.
  • Specialized knowledge of quality system regulations and standards relevant to the role, including EU MDR, ISO 13485, ISO 9001, Good Manufacturing Practices 21 CFR 820, and Good Documentation Practices, along with auditing experience.
  • Experience developing or supporting test methods, including MSA, Gage R&R, and TMV; product and process validation protocols and reports; risk assessments such as pFMEAs and dFMEAs; Design of Experiments; and capability analyses.
  • Experience applying procedures and concepts within the candidate's discipline, plus basic knowledge of other disciplines.
  • Ability and interest in learning new products, manufacturing processes, control requirements, governance procedures, and customer requirements.
  • Ability to make timely decisions in a fast-paced, complex production environment and maintain a calm demeanor amid changing production and customer conditions.
Responsibilities
  • Lead assigned manufacturing site or sites to ensure customer requirements are met while maintaining compliance with quality management system policies and procedures.
  • Lead, coach, and develop a team of Quality professionals, including Quality Supervisors, Quality Engineers, and individual contributors.
  • Define and champion the evolution of the local Quality System to align with Integer's overarching QMS.
  • Own the local quality management system, including Management Review, CAPA, complaint handling, document change management, design control, production control, internal and customer nonconformance management, supplier quality audits, and internal QMS audits.
  • Serve, as applicable, as the management representative.
  • Follow company policies, safety and quality requirements, QMS and EMS requirements, U.S. FDA regulations, operating procedures, and other location-specific regulatory requirements.
  • Prevent and correct quality-related gaps in processes and systems and drive process improvements.
  • Establish team objectives, ensure effective team communications, and support team members in pursuing their Individual Development Plans.
  • Build a culture of quality across the team, site, and/or business and ensure compliance with the established Quality Management System.
  • Serve as a regular interface with internal and external customers.
  • Contribute to the site or business Hoshin plan by specifying and prioritizing quality initiatives.
  • Complete assigned projects and manage risks associated with quality concerns.
  • Provide input into and manage the department budget, strategic plans, and quality plans.
  • Support the team in initiating and completing rigorous root cause analyses; recommend and coordinate cross-functional or organizational support to resolve issues as needed.
  • Champion development and deployment of systems and tools that promote innovation and continuous improvement within the Quality Management System.
  • Ensure investigation and disposition of nonconforming materials meet internal and customer requirements and that corrective actions prevent recurrence.
  • Lead and manage product complaint investigations.
  • Initiate and facilitate plant CAPA activities resulting from analysis of complaints, supplier quality, nonconforming material, training effectiveness, and root causes.
  • Establish root causes of product and process failures through process observation and data analysis, and drive appropriate improvement activities.
  • Support the Integer Production System through site Hoshin plans, quality planning meetings, participation as Quality representative in site Plant Leadership meetings, and site-wide communications.
  • Identify opportunities to improve processes and products and ensure changes comply with customer contractual obligations and regulatory requirements.
  • Promote standardization through workplace organization and visual controls, Manufacturing Standard Work, robust training and certification programs, and Quality policies and procedures aligned with the enterprise QMS.
  • Promote associate engagement through collaborative problem-solving, behavior-based safety programs, and improvement idea and suggestion systems.
  • Optimize systems and processes through built-in quality, optimized scheduling and material system designs, work-cell design, and total productive maintenance.
  • Support Environmental, Health, and Safety programs.
  • Define goals and objectives, including key projects and milestones, and deliver against site or business quality metrics, customer shipments, and assigned project milestones.
  • Lead the team in generating continuous-improvement suggestions and supporting their implementation.
  • Promote associate engagement and the professional growth and development of direct reports, and ensure Associate Relations issues are handled in a timely manner.
  • Perform other duties as needed and directed by the manager.
Desired Qualifications
  • Quality-related certifications such as Six Sigma Green Belt, ASQ Certified Manager of Quality, ASQ Quality Auditor, or other related certifications.
  • Ability to articulate a personal leadership strategy, create and share a strategic vision, and align a team to achieve that vision.
  • Leadership skills aligned with Integer's values.

About the company

I

Integer Holdings Corporation

View

Integer Holdings Corporation is a large medical device contract development and manufacturing organization (CDMO) that supports medical device makers in cardiac rhythm management, neuromodulation, and cardiovascular markets. It provides end-to-end services from design support to manufacturing, delivering components and finished subsystems such as implants, housings, electrodes, and batteries through its Greatbatch Medical, Lake Region Medical, and Electrochem brands. The company differentiates itself by its scale, breadth of capabilities across multiple medical specialties, established brand portfolio, and global manufacturing footprint that enable reliable, integrated supply. Its goal is to improve patients’ lives worldwide by helping customers bring safe and effective medical technologies to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

1940

Get referred to Integer Holdings Corporation

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $464.1 million, beating estimates despite weak medtech demand.
  • Integer expects demand recovery after New Ross's July 27-August 10, 2026 shutdown.
  • KKR plans new capacity, technology, and employee ownership after closing by year-end 2026.

What critics are saying

  • Integer withdrew 2026 guidance on August 3, 2026, after KKR announced the buyout.
  • Schall, Brown & Schwartz opened an August 23, 2026 fiduciary-duty investigation.
  • Regulatory or stockholder rejection kills the KKR deal and leaves Integer's weak standalone outlook exposed.

What makes Integer Holdings Corporation unique

  • Integer's R&D Velocity integrates design, prototyping, and manufacturing for complex medtech programs.
  • Its 33-facility global network spans electrophysiology, neuromodulation, and structural heart.
  • KKR's August 3, 2026, $5.7 billion bid validates Integer's scale and customer lock-in.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Adoption Assistance

Parental Leave

401(k) Company Match

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

-1%
Ticker Report
Aug 29th, 2026
Boussard & Gavaudan Gestion Sas Makes New $2.60 Million Investment in Integer Holdings Corporation $ITGR

Boussard & Gavaudan Gestion Sas bought a new position in Integer Holdings Corporation (NYSE:ITGR – Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 28,153 shares of the medical equipment provider’s stock, valued at approximately $2,597,000. Other institutional investors and hedge funds also […]

Yahoo Finance
Aug 16th, 2026
Healthcare stocks outpace S&P 500 by 13 percentage points over six months

Healthcare stocks have returned 26.1% over the past six months, outperforming the S&P 500 by 13.1 percentage points. However, investors must remain cautious due to heavy regulation affecting earnings potential. Integer Holdings faces concerns with 6.1% annual revenue growth over two years, lagging healthcare peers. Its modest revenue base of $1.84 billion provides less fixed cost leverage than larger competitors. The company trades at $125.07 per share, or 18.6 times forward price-to-earnings. Evolent Health shows weak platform performance and declining returns on capital. Its high net-debt-to-EBITDA ratio of 7 times could force unfavourable capital raises if market conditions worsen. Shares trade at $4.15, representing 12.4 times forward price-to-earnings. Tenet Healthcare, operating hospitals and surgical centres across nine US states, emerges as the recommended healthcare investment.

Yahoo Finance
Aug 4th, 2026
Integer Holdings acquired by KKR for $5.7B in all-cash deal at $127 per share

Integer Holdings agreed to be acquired by private equity firm KKR in an all-cash deal valued at approximately $5.7 billion. The transaction values the medical technology company at $127 per share. Shares jumped 2.7% in afternoon trading, continuing a rally from the previous session when the stock surged over 20% following the announcement. The acquisition news overshadowed strong second-quarter results, where Integer posted an adjusted profit of $1.60 per share on $464.1 million in revenue, surpassing analyst estimates. Following the buyout announcement, Integer withdrew its previously issued financial guidance and cancelled its upcoming earnings conference call. Shares traded at $124.50, marking a new 52-week high.

BizWire Express
Aug 3rd, 2026
KKR to acquire Integer for $5.7B in all-cash deal at $127 per share

KKR has agreed to acquire Integer Holdings Corporation, a medical device contract development and manufacturing organisation, in an all-cash transaction valued at approximately $5.7 billion. Integer stockholders will receive $127 per share, representing a 51.8% premium to the company's closing share price on 29 April 2026. The acquisition follows a comprehensive strategic review announced by Integer in April 2026. The Integer Board unanimously approved the agreement and recommends stockholder approval. KKR plans to invest in Integer's capacity, technology, innovation, and talent. The firm also intends to establish a broad-based employee ownership programme following the transaction's close, consistent with its approach across portfolio companies. The transaction is expected to close by year-end, subject to stockholder approval and regulatory clearances. Upon completion, Integer will become privately held and delist from the New York Stock Exchange.

Yahoo Finance
Aug 3rd, 2026
Integer Holdings beats Q2 expectations with $464M revenue and $1.60 earnings per share

Integer Holdings Corp. reported second-quarter net income of $23.6 million, or 69 cents per share. Adjusted earnings came to $1.60 per share, exceeding Wall Street expectations of $1.38 per share. The Plano, Texas-based medical device outsource manufacturer posted revenue of $464.1 million for the period, also beating analyst forecasts of $452.5 million. The results surpassed predictions from five analysts surveyed by Zacks Investment Research on both earnings and revenue metrics.